Pamela Cramer - Rhythm Pharmaceuticals Chief Officer
| RYTM Stock | USD 59.94 0.91 1.54% |
Insider
Pamela Cramer is Chief Officer of Rhythm Pharmaceuticals
| Age | 50 |
| Address | 222 Berkeley Street, Boston, MA, United States, 02116 |
| Phone | 857 264 4280 |
| Web | https://rhythmtx.com |
Pamela Cramer Latest Insider Activity
Tracking and analyzing the buying and selling activities of Pamela Cramer against Rhythm Pharmaceuticals stock is an integral part of due diligence when investing in Rhythm Pharmaceuticals. Pamela Cramer insider activity provides valuable insight into whether Rhythm Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Rhythm Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Rhythm Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Pamela Cramer over two months ago Disposition of 3200 shares by Pamela Cramer of Rhythm Pharmaceuticals at 50.0056 subject to Rule 16b-3 | ||
Pamela Cramer over three months ago Disposition of 3125 shares by Pamela Cramer of Rhythm Pharmaceuticals subject to Rule 16b-3 |
Rhythm Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4624) % which means that it has lost $0.4624 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.479) %, meaning that it created substantial loss on money invested by shareholders. Rhythm Pharmaceuticals' management efficiency ratios could be used to measure how well Rhythm Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Tangible Assets is likely to drop to -0.6. In addition to that, Return On Capital Employed is likely to grow to -0.63. At this time, Rhythm Pharmaceuticals' Non Current Assets Total are very stable compared to the past year. As of the 25th of November 2024, Non Currrent Assets Other is likely to grow to about 16.1 M, while Other Current Assets are likely to drop about 5.8 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| CPA CPA | Arvinas | 52 | |
| MBA MBA | Inozyme Pharma | 65 | |
| Steve Andre | Cullinan Oncology LLC | N/A | |
| CMO MBA | Viridian Therapeutics | 72 | |
| Matthew JD | Arvinas | 49 | |
| Kevin Giordano | Rocket Pharmaceuticals | N/A | |
| Darlene Noci | Nuvalent | 46 | |
| Prof Davis | Avidity Biosciences | N/A | |
| Isabel Aznarez | Stoke Therapeutics | 52 | |
| CPA CPA | Stoke Therapeutics | 63 | |
| Prof MD | Ventyx Biosciences | N/A | |
| Kevan Shokat | Revolution Medicines | N/A | |
| Peter BSc | Syndax Pharmaceuticals | 55 | |
| MA MBA | Relay Therapeutics | 48 | |
| David Cerveny | Uniqure NV | 57 | |
| ric MD | Pliant Therapeutics | 60 | |
| JD Esq | Black Diamond Therapeutics | 59 | |
| Michael MBA | Arcellx | N/A | |
| MBA MD | Pliant Therapeutics | 56 | |
| Andy Porter | Relay Therapeutics | N/A | |
| M MBA | Rocket Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -1.48 | ||||
| Return On Asset | -0.46 |
Rhythm Pharmaceuticals Leadership Team
Elected by the shareholders, the Rhythm Pharmaceuticals' board of directors comprises two types of representatives: Rhythm Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rhythm. The board's role is to monitor Rhythm Pharmaceuticals' management team and ensure that shareholders' interests are well served. Rhythm Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rhythm Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer Lee, Executive America | ||
| Yann Mazabraud, Executive International | ||
| Christopher German, Principal Controller | ||
| Sarah Ryan, Vice Marketing | ||
| Jim Flaherty, Senior Counsel | ||
| David Connolly, Head Communications | ||
| Joseph Shulman, Chief Officer | ||
| Jennifer Chien, Ex America | ||
| Pamela Cramer, Chief Officer | ||
| Alastair Garfield, Chief Officer | ||
| William Roberts, Chief Officer | ||
| David MD, President Chairman | ||
| Hunter MBA, CFO Treasurer |
Rhythm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rhythm Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.48 | ||||
| Return On Asset | -0.46 | ||||
| Profit Margin | (2.30) % | ||||
| Operating Margin | (1.32) % | ||||
| Current Valuation | 3.39 B | ||||
| Shares Outstanding | 61.46 M | ||||
| Shares Owned By Insiders | 0.52 % | ||||
| Shares Owned By Institutions | 99.48 % | ||||
| Number Of Shares Shorted | 8.36 M | ||||
| Price To Book | 328.47 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rhythm Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share 1.863 | Quarterly Revenue Growth 0.478 | Return On Assets (0.46) | Return On Equity (1.48) |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.